Clinical Responses Articles & Analysis: Older
51 news found
Clinical Trial Manager roles are growing 32% faster than the national average. This job is undeniably rewarding but requires a high level of expertise and a knack for research. A clinical trial manager is responsible for many tasks, including overseeing everything from creating a valid test to its administration, recruitment, ...
About the webinar 2020/21 led to significant clinical trial innovation in clinical trials in response to the Covid-19 pandemic with 2022 providing key insights, projects and lessons in the wider clinical trials space. 2023 will see these lessons merge with long-term trends and the lessons from important pilot programs to see ...
ByStatsol
“But in many instances, the Cellworks Platform has the ability to predict the human clinical response to drug candidates years earlier than traditional development pipelines. By predicting human clinical response much earlier in the drug development cycle, we can help pharmaceutical companies shave years off drug ...
The study titled, “Pressure-Volume Profiles in Heart Failure Across Sexes and Phenotypes,” assessed the relationship between cardiac filling pressures (a commonly used surrogate to assess blood volume) and total blood volume (TBV) measurement using Daxor’s BVA-100 blood test between sexes and left ventricular ejection fraction (LVEF), key clinical determinants ...
In the MANIFEST study, changes in biomarkers correlated with improvements in clinical measures of treatment success (SVR35, TSS50 and hemoglobin increases indicative of improved anemia), suggesting a potential disease-modifying effect of pelabresib. ...
The last patient in the investigator-initiated clinical trial DIAGNODE-B has received its additional injection (“booster”) of the therapeutic diabetes vaccine Diamyd®. ...
A novel RNA-based IL-2 treatment response classifier was developed as part of the study in patients with renal cell carcinoma Durham, NC, August 23, 2022 – GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced its new publication in Cancer Research Communications that compares the immunogenomic ...
Analyses also showed a positive immunological response to the treatment and the clinical course appears promising with all individuals remaining insulin-independent 12 months after treatment. ...
” The group of New England clinicians described several ways that preventing IV dislodgement could improve clinical quality. Their responses included: Reducing IV restarts Less trauma to patients by reducing restart-related needlesticks Preserving patient veins for subsequent procedures Maintaining IV access in emergency and critical care situations, ...
Rizo has served most recently as Executive Vice President and Chief Medical Officer of Geron Corporation since January 2019 where she provided leadership and direction for all clinical and translational efforts. Included in her reporting responsibilities were clinical development, clinical operations, clinical ...
ByBayer AG
Kidney transplant recipients who do not develop BKVN have been shown to have approximately 10-fold higher BKV-specific T-cell responses versus those with BKVN. Kidney transplant recipients with BK viremia who develop robust BKV-specific T-cell responses have also been shown to clear the virus, while those who progressed to BKVN required interventions such as ...
ByKalaris
(Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that new tumor response and overall survival (OS) data from the ongoing Phase 2a study of VBI-1901, the Company’s cancer vaccine immunotherapeutic candidate, in recurrent glioblastoma (GBM) was presented at the 2022 American ...
(VIDA), the leader in lung and respiratory intelligence data, is introducing a new suite of retrospective data analysis services for clinical trial sponsors in response to growing demand for precision data to optimize lung treatment trials. ...
Kheiron Medical Technologies today announced the appointment of Dr. Wendy DeMartini, Dr. Elizabeth Morris, and Dr. Amy Patel to its US Breast Medical Advisory Board. These appointments reinforce Kheiron’s focus on bringing its artificial intelligence solutions to the US market to help radiologists detect breast cancer earlier. Kheiron is committed to assembling an inclusive advisory board ...
The publication highlights key results including that SER-109 was superior to placebo in reducing CDI recurrence, with 88% of SER-109 patients achieving a sustained clinical response compared to 60% on placebo. SER-109 was well tolerated, with a side effect profile comparable to placebo and no serious drug-related adverse events observed. SER-155 Phase 1b ...
AlloVir (Nasdaq: ALVR), a late clinical-stage allogeneic T cell immunotherapy company, today announced that the U.S. ...
ByKalaris
This feature provides a comprehensive, consistent, and automated analysis of biomarkers from next-generation sequencing (NGS) and microarray data that can help clinical researchers stratify therapeutic response across multiple tumor types. ...
The primary study endpoint is the number of new-onset clinically significant infections or end-organ disease through Week 14. ...
ByKalaris
Nathan joins from BenevolentAI, where he led the Cheminformatics team and was responsible for the research and development of new and effective approaches for computational drug design. ...
Mersana will collaborate with Janssen on target candidates during preclinical development, with Janssen being solely responsible for clinical development and commercialization. Mersana will receive an upfront payment of $40 million. ...